Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Hodgkin
lymphoma
(
HL
)
is
a
B
cell-derived
lymphoid
malignancy
most
often
affecting
young
adults
.
More
than
80
%
of
HL
patients
achieve
long
-term
remission
after
appropriate
first
-line
treatment
consisting
of
multiagent
chemotherapy
and
/
or
radiotherapy
(
RT
)
.
In
addition
,
approximately
50
%
of
patients
with
disease
recurrence
remain
relapse-free
after
salvage
therapy
with
high
-dose
chemotherapy
followed
by
autologous
stem
cell
transplantation
(
ASCT
)
.
However
,
patients
with
multiple
relapses
are
mostly
in
a
palliative
situation
,
and
novel
drugs
for
this
patient
group
are
needed
.
Furthermore
,
novel
less
toxic
but
equally
effective
first
-line
and
second
-line
approaches
are
required
as
therapy-related
late
sequelae
represent
a
relevant
cause
of
morbidity
and
mortality
in
HL
survivors
.
Several
antibodies
and
antibody-drug
conjugates
(
ADC
)
targeting
CD
30
and
CD
2
0
have
recently
been
evaluated
in
HL
.
Excellent
response
rates
in
heavily
pretreated
patients
were
observed
with
the
ADC
brentuximab
vedotin
directed
against
CD
30
.
Thus
,
ongoing
trials
investigate
brentuximab
vedotin
in
different
additional
indications
.
One
example
is
the
first
-line
treatment
of
advanced
HL
where
the
drug
is
currently
being
evaluated
in
combination
with
variants
of
the
first
-line
protocols
ABVD
(
adriamycin
,
bleomycin
,
vinblastine
,
dacarbazine
)
and
escalated
BEACOPP
(
bleomycin
,
etoposide
,
adriamycin
,
cyclophosphamide
,
vincristine
,
procarbazine
,
prednisone
)
.
Anti-
CD
2
0
antibodies
given
either
as
single
agent
or
in
combination
with
conventional
chemotherapy
have
also
been
investigated
and
still
undergo
investigation
in
prospective
studies
including
HL
patients
.
This
article
reviews
the
available
data
on
treatment
approaches
including
antibodies
and
ADC
in
HL
patients
.
Diseases
Validation
Diseases presenting
"single agent"
symptom
coats disease
esophageal squamous cell carcinoma
hodgkin lymphoma, classical
severe combined immunodeficiency
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom